Meta-analysis of Stroke and Bleeding Risk in Patients with Various Atrial Fibrillation Patterns Receiving Oral Anticoagulants
Autor: | Lingling Yu, You-Wen Xiong, Ai-Zhen Xiong, Huihui Bao, Xiaoshu Cheng, Weifang Zhang |
---|---|
Rok vydání: | 2019 |
Předmět: |
medicine.medical_specialty
Administration Oral Hemorrhage 030204 cardiovascular system & hematology Cochrane Library Global Health Lower risk law.invention 03 medical and health sciences 0302 clinical medicine Randomized controlled trial Risk Factors law Internal medicine Atrial Fibrillation medicine Humans 030212 general & internal medicine Stroke business.industry Incidence Incidence (epidemiology) Anticoagulants Atrial fibrillation medicine.disease Meta-analysis Relative risk Cardiology Cardiology and Cardiovascular Medicine business |
Zdroj: | The American Journal of Cardiology. 123:922-928 |
ISSN: | 0002-9149 |
Popis: | Oral anticoagulation therapy (OAT) is a mainstay for stroke prevention in atrial fibrillation (AF) patients. However, whether the risks of stroke/systemic embolic events (SEE) and bleeding events are affected by the type, duration, and frequency of AF in patients receiving OAT has been previously debated. We aimed to determine the risk of stroke/SEE and bleeding events associated with paroxysmal AF compared to persistent or permanent AF among patients who received OAT. Comprehensive literature searches of the Cochrane Library, PubMed/MEDLINE, and EMBASE databases were conducted from inception to July 2018. In total, 495 records were retrieved, of which 6 phase III randomized controlled trials (RCTs) focusing on the efficacy and safety of OAT in AF patients were ultimately evaluated and included. Among 70,447 AF patients, 15,028 (21.3%) patients had paroxysmal and 55,419 (78.7%) had persistent or permanent AF. Compared to persistent or permanent AF, the incidence of stroke/SEE was lower in paroxysmal AF patients (risk ratio [RR] 0.79, 95% confidence interval [CI] 0.71 to 0.88, P |
Databáze: | OpenAIRE |
Externí odkaz: |